Physician Research Collaboration — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$373,946	41
2024	Research	$570,739	91
2023	Research	$787,646	248
2022	Research	$1,091,792	420
2021	Research	$566,146	178
2020	Research	$413,461	52
2019	Research	$92,126	6

Breakdown

Who paid Research payments · program years 2019–2025

Sun Pharmaceutical Industries Inc. $1,700,542 592 payments
Novartis Pharmaceuticals Corporation $1,529,700 29 payments
AbbVie, Inc. $354,711 162 payments
GlaxoSmithKline, LLC. $220,193 239 payments
Noven Pharmaceuticals, Inc. $86,314 12 payments
AstraZeneca UK Limited $4,060 1 payment
E.R. Squibb & Sons, L.L.C. $336 1 payment

Studies the money was for Research payments · program years 2019–2025

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) $949,187 305 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $465,654 7 payments
INSPIRE LTE study $445,769 88 payments
An Open-Label, Multi-Center Protocol for Patients Who Have Completed A Previous Novartis Sponsored Secukinumab Study and Are Judged By the Investigator to Benefit From Continued Secukinumab Treatment $332,664 2 payments
A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $211,642 214 payments
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $197,050 114 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Psoriatic Arthritis $171,300 3 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Psoriatic Arth $137,105 3 payments
A Randomized Partially Blinded Active Controlled Multicenter Study of Ecukinumab to Demonstrate Reduction of Radiographic Progression Versus Gp2017 Adalimumab Biosimilar at 104 Weeks and to Assess the Long Term Safety Tolerability and Efficacy Up to 2 Yea $135,215 3 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $122,418 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.